12. Segments

6 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Segments

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Six Months Ended September 30,
	2017			2016
Revenues:
Aethlon	$	–		$	392,073
ESI		–			–
Total Revenues	$	–		$	392,073
Operating Losses:
Aethlon	$	(2,373,066	)	$	(3,281,530	)
ESI		(23,356	)		(76,999	)
Total Operating Loss	$	(2,396,422	)	$	(3,358,529	)
Net Losses:
Aethlon	$	(3,130,772	)	$	(4,323,003	)
ESI		(23,356	)		(76,999	)
Net Loss Before Non-Controlling Interests	$	(3,154,128	)	$	(4,400,002	)
Cash:
Aethlon	$	919,612		$	553,884
ESI		460			2,468
Total Cash	$	920,072		$	556,352
Total Assets:
Aethlon	$	1,118,433		$	914,179
ESI		27,545			36,656
Total Assets	$	1,145,978		$	950,835
Capital Expenditures:
Aethlon	$	23,705		$	2,961
ESI		–			–
Capital Expenditures	$	23,705		$	2,961
Depreciation and Amortization:
Aethlon	$	18,651		$	10,822
ESI		–			9,790
Total Depreciation and Amortization	$	18,651		$	20,612
Interest Expense:
Aethlon	$	(250,583	)	$	(78,743	)
ESI		–			–
Total Interest Expense	$	(250,583	)	$	(78,743	)